



























- production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. *Blood*, 95(2): 610-8.  
<http://doi.org/10.1182/blood.V95.2.610>
- Tyagi P, Li Z, Chancellor M, et al., 2004. Sustained intravesical drug delivery using thermosensitive hydrogel. *Pharm Res*, 21(5): 832-7.  
<http://doi.org/10.1023/b:pham.0000026436.62869.9c>
- Verri WA, Jr., Cunha TM, Ferreira SH, et al., 2007. IL-15 mediates antigen-induced neutrophil migration by triggering IL-18 production. *Eur J Immunol*, 37(12): 3373-80.  
<http://doi.org/10.1002/eji.200737488>
- Waldmann TA, 2015. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. *Cancer Immunol Res*, 3(3): 219-27.  
<http://doi.org/10.1158/2326-6066.Cir-15-0009>
- Waldmann TA, Lugli E, Roederer M, et al., 2011. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. *Blood*, 117(18): 4787-95.  
<http://doi.org/10.1182/blood-2010-10-311456>
- Wang W, Zhang P, Shan W, et al., 2013. A novel chitosan-based thermosensitive hydrogel containing doxorubicin liposomes for topical cancer therapy. *J Biomater Sci Polym Ed*, 24(14): 1649-59.  
<http://doi.org/10.1080/09205063.2013.789357>
- Wang X, Li J, Wang Y, et al., 2009. HFT-T, a targeting nanoparticle, enhance specific delivery of paclitaxel to folate receptor-positive tumors. *ACS Nano*, 3(10): 3165-74.  
<http://doi.org/10.1021/nn900649v>
- World Health Organization, 2018. BCG vaccine: WHO position paper, February 2018 - Recommendations. *Vaccine*, 36(24): 3408-3410.  
<http://doi.org/10.1016/j.vaccine.2018.03.009>
- Wu JJ, Zhao L, Hu HG, et al., 2020. Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy. *Med Res Rev*, 40(3): 1117-1141.  
<http://doi.org/10.1002/med.21649>
- Wurpel DJ, Beatson SA, Totsika M, et al., 2013. Chaperone-usher fimbriae of Escherichia coli. *PLoS One*, 8(1): e52835.  
<http://doi.org/10.1371/journal.pone.0052835>
- Yamada H, Matsumoto S, Matsumoto T, et al., 2000. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. *J Urol*, 164(2): 526-31.  
[http://doi.org/10.1016/S0022-5347\(05\)67417-4](http://doi.org/10.1016/S0022-5347(05)67417-4)
- Yamamoto S, Tsukamoto T, Terai A, et al., 1997. Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by Escherichia coli. *J Urol*, 157(3): 1127-9.  
[http://doi.org/10.1016/S0022-5347\(01\)65154-1](http://doi.org/10.1016/S0022-5347(01)65154-1)
- Zaharoff DA, Hoffman BS, Hooper HB, et al., 2009. Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. *Cancer Res*, 69(15): 6192-9.  
<http://doi.org/10.1158/0008-5472.Can-09-1114>
- Zhang D, Sun P, Li P, et al., 2013. A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette-Guerin in the treatment of bladder cancer. *Biomaterials*, 34(38): 10258-66.  
<http://doi.org/10.1016/j.biomaterials.2013.09.027>
- Zhang L, Gu FX, Chan JM, et al., 2008. Nanoparticles in medicine: therapeutic applications and developments. *Clin Pharmacol Ther*, 83(5): 761-9.  
<http://doi.org/10.1038/sj.clpt.6100400>
- Zhang W, Xu L, Park HB, et al., 2020. Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy. *Nat Commun*, 11(1): 1187.  
<http://doi.org/10.1038/s41467-020-15030-4>
- Zhang Y, Huo F, Cao Q, et al., 2022. FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer. *J Immunother Cancer*, 10(3).  
<http://doi.org/10.1136/jitc-2021-003939>